Please Note: This trial is no longer enrolling new participants
A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination with mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants with KRAS G12D-mutated Metastatic Pancreatic Adenocarcinoma
| Protocol No. | CTO-3082-CL-0301 | Scope | National |
|---|---|---|---|
| Principal Investigator | Anita Turk | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase III |
